Details for Patent: 10,047,053

« Back to Dashboard

Which drugs does patent 10,047,053 protect, and when does it expire?

Patent 10,047,053 protects ALYFTREK and is included in one NDA.

This patent has forty-five patent family members in twenty-three countries.

Summary for Patent: 10,047,053

Title:	Deuterated CFTR potentiators
Abstract:	This invention relates to compounds of Formula I: and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a CFTR potentiator.
Inventor(s):	Adam J. Morgan
Assignee:	Vertex Pharmaceuticals Europe Ltd
Application Number:	US15/827,792
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,047,053
Patent Claim Types: see list of patent claims	Use; Compound;

Drugs Protected by US Patent 10,047,053

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Vertex Pharms Inc	ALYFTREK	deutivacaftor; tezacaftor; vanzacaftor calcium	TABLET;ORAL	218730-001	Dec 20, 2024		RX	Yes	No	10,047,053			Y
Vertex Pharms Inc	ALYFTREK	deutivacaftor; tezacaftor; vanzacaftor calcium	TABLET;ORAL	218730-002	Dec 20, 2024		RX	Yes	Yes	10,047,053			Y

International Family Members for US Patent 10,047,053

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2012255711
Australia	2017208313
Australia	2019222862